Yeah the valuation...
In 12 months, ANP would be well into the 'pivotal' open label study...concurrently in US and Europe....hopefully with one or two Big Pharma gorillas as partners.
With ODD on hand for both markets and 7 to 10 years of exclusivity....the DMD $6B market alone will get us a valuation well north of $1.50 imo.
I agree with Sammy, lets list on NASDAQ.
